Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

Tetje C. van der Sluis1, Marjolein Slijter2, Suzanne van Duikeren1, Brian L. West3, Cornelis J.M. Melief1,4, Ramon Arens1, Sjoerd H. van der Burg2, and Thorbald van Hall2.

Abstract

Abundant macrophage infiltration of solid cancers commonly correlates with poor prognosis. Tumor-promoting functions of macrophages include angiogenesis, metastasis formation, and suppression of Th1-type immune responses. Here, we show that successful treatment of cervical carcinoma in mouse models with synthetic long peptide (SLP) vaccines induced influx of cytokine-producing CD8 T cells that strongly altered the numbers and phenotype of intratumoral macrophages. On the basis of the expression of CD11b, CD11c, F4/80, Ly6C, Ly6G, and MHC II, we identified four myeloid subpopulations that increased in numbers from 2.0-fold to 8.7-fold in regressing tumors. These changes of the intratumoral myeloid composition coincided with macrophage recruitment by chemokines, including CCL2 and CCL5, and were completely dependent on a vaccine-induced influx of tumor-specific CD8 T cells. CD4 T cells were dispensable. Induction of tumor cells with T cell–derived IFNγ and TNFα recapitulated the chemokine profile observed in vivo, confirming the capacity of antitumor CD8 T cells to mediate macrophage infiltration of tumors. Strikingly, complete regressions of large established tumors depended on the tumor-infiltrating macrophages that were induced by this immunotherapy, because a small-molecule drug inhibitor targeting CSF-1R diminished the number of intratumoral macrophages and abrogated the complete remissions. Survival rates after therapeutic SLP vaccination deteriorated in the presence of CSF-1R blockers. Together, these results show that therapeutic peptide vaccination could induce cytokine-producing T cells with strong macrophage-skewing capacity necessary for tumor shrinkage, and suggest that the development of macrophage-polarizing, rather than macrophage-depleting, agents is warranted. Cancer Immunol Res; 3(9): 1042–51. © 2015 AACR.

Introductions

Cervical cancer is strongly associated with human papillomavirus (HPV) infection (1, 2). The two HPV oncoproteins E6 and E7 are critical for maintenance of cellular transformation; they are constitutively expressed by HPV-associated tumors and are therefore ideal targets for therapeutic vaccination (3). We have shown that overlapping synthetic long overlapping peptides (SLP) comprising these proteins are capable of inducing potent T-cell responses in patients with gynecologic carcinoma, there is no apparent effect on survival (8, 9), suggesting that the induction of a measurable T-cell response alone is not sufficient for a therapeutic effect.

Practical data from mice models of HPV16-induced malignancies suggest that tumor infiltration of macrophages [tumor-associated macrophages (TAM)] causes suppression of antitumor T-cell responses, thereby facilitating tumor growth (10). In fact, abundant infiltration of TAMs correlates with poor prognosis in most human cancers, and these macrophages are characterized by a “tissue-repair” function, via production of epithelial growth factors and stimulation of angiogenesis, tissue remodeling, and immunoregulatory functions. This M2-like differentiation program also includes suppression of Th1-mediated cytotoxic immune responses in order to minimize tissue damage (11, 12). Therefore, TAM functions are often compared with those in wound-healing responses in which cytotoxic immunity is damped. This role of myeloid cells in the local tumor microenvironment (TME) is the subject of extensive studies in mouse tumor models and human cancer (11, 12).

The myeloid compartment is very heterogeneous, and circulating monocytes can differentiate toward M1-type macrophages that support Th1-polarized immunity and mediate killing of bacteria (13). Skewing TAMs toward this “classically” activated phenotype can result in antitumor activity and clearance of established tumors, indicating that tumor-associated myeloid cells might hold the key to switching the local immune system to a tumor-rejection response (14, 15). Silencing of the NF-κB pathway through targeting of IKKβ in macrophages was shown to result in such a desirable differentiation (14, 15). We demonstrated that a combination of IFNγ and CD40L signals prevents...
cancer-induced M2-type differentiation (16). Interestingly, low-dose local radiotherapy and anthracyclin-type chemotherapies were shown to program macrophage differentiation to support intratumoral recruitment of CD8 T cells (17, 18). Therapy-induced inflammatory macrophages were responsible for uptake and presentation of tumor antigens to T cells, thereby leading to effective antitumor immunity.

Long peptide cancer vaccines are strong immunogens and are capable of inducing regressions in experimental mouse tumors and premalignant lesions in patients (4, 6). We use two models of HPV-induced malignancies and show that only when therapeutic vaccination with SLP induces influx of cytokine-producing CD8 T cells, the tumor cells produce myeloid-cell attracting and skewing chemokines. Indeed, TC-1 tumors of vaccinated mice are massively infiltrated by myeloid cells with a preponderance of inflammatory macrophages, whereas identical therapeutic vaccination in mice with C3 tumors has no effect. Importantly, we found that macrophages critically contributed to vaccine-induced tumor regressions. Complete tumor shrinkage induced by this CD8 T cell–based immunotherapy was lost when macrophages were targeted by CSF-1R inhibitors. Together, our data indicate an essential role for intratumoral macrophages during immunotherapy and argue for macrophage-skewing, rather than macrophage-depleting, strategies for future clinical development.

Materials and Methods

Mice

C57BL/6jico female mice were purchased from Charles River Laboratories and housed in the animal facility of the Leiden University Medical Center (Leiden, the Netherlands). All mice were maintained under specific pathogen-free conditions and at 8 weeks of age. Experiments on mice were approved by the local university committee for the care of laboratory animals, in line with guidelines of the European Committee.

Tumor cell lines

The tumor cell line TC-1 (a gift from T.C. Wu, John Hopkins University, Baltimore, MD) was produced and maintained as previously described (6). The tumor cell line C3 was generated by transfection of B6 mouse embryonic cells with the complete HPV16 genome and maintained as previously described (19). Both cell lines were tested by PCR for rodent viruses, most recently every 6 months by PCR. Mycoplasma detection was performed twice monthly by PCR.

Analysis of cytokine expression levels.

To analyze the presence of antigen-specific T cells, blood of vaccinated mice was stained for CD8α and CD3 combined with HPV16 E79–57 (RAHYNIVTF) MHC class I (H-2Db) tetramer. For analysis of tumor-infiltrating populations, mice were sacrificed 10 days after SLP, transcardially perfused, and tumors of similar size were harvested, disrupted in small pieces, and incubated with Liberase (Roche) in Iscove’s modified Dulbecco’s medium (IMDM) for 15 minutes at 37°C. Single-cell suspensions were prepared by mincing the tumors through a 70-μm cell strainer (BD Biosciences). Cells were resuspended in staining buffer (PBS + 2% FCS + 0.05% sodium azide) and incubated with antibodies to Ly6C (FITC), Ly6G (Alexa 700), F4/80 (PE), CD11c (BV605), CD11b (eFluor 450), allophycocyanin (APC)–labeled H-2Db tetramers containing HPV16 E79–57 peptide, 7-aminoactinomycin D (for dead-cell exclusion; Invitrogen), CD8α (A700), CD3 (Pacific Blue), CD45.2 (HTC/Alexa 780), and Class II (V500), for 30 minutes at 4°C. Fluorescent-conjugated antibodies were purchased from BD Biosciences, BioLegend, and eBioscience. To analyze the intracellular cytokine production of circulating CD8 T cells, blood was incubated for 5 hours with HPV16 E79–57 peptide. For analysis of cytokine production by T cells, single-cell suspensions of tumor (-infiltrate) were incubated for 5 hours with 40,000 D1 cells loaded with the HPV16 E79–57 (2 μg/mL) peptide in the presence of Brefeldin A (2 μg/mL). After cell-surface staining with fluorescein-labeled antibodies to mouse CD45, CD8, and CD3, overnight fixation with 0.5% paraformaldehyde solution, and permeabilization with Perm/Wash buffer (BD Biosciences), cells were stained at 4°C with fluorescein-labeled antibodies against IFNγ (APC) and TNFα (FITC). Samples were analyzed with a BDLSR II flow cytometer, and results were analyzed using the FlowJo software (TreeStar).

Quantitative real-time PCR

**Tumor material.** Tumors from perfused mice were embedded in Tissue-Tek and immediately frozen in cooled 2-methylbutane. RNA was isolated from 20 sections of 20 μm.

**In vitro chemokine expression levels.** TC-1 tumor cells were harvested and seeded at 1.2 × 106 cells per well onto a 1.6 × 105 cells per well (6-well plate). After 24 hours, TC-1 cells were incubated with 20 ng TNFα and/or 200 ng IFNγ and C3 with 10 ng TNFα and/or 40 ng IFNγ. Twenty-two hours later, tumor
cells were harvested, washed in PBS, and snap-frozen in liquid nitrogen.

RNA from in vitro and in vivo samples was isolated using an RNaseasy Mini kit (Qiagen) according to the manufacturer’s protocol. cDNA synthesis was performed using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Reactions were performed using iQ SybrGreen supermix (Bio-Rad) on the CFX384 Real-Time PCR Detection System (Bio-Rad) with an annealing temperature of 60°C. Cycle threshold (Ct) values were normalized to the expression levels of GAPDH and β-actin genes (ΔΔCt). The difference between the individual ΔΔCt and the average expression was calculated for each gene and expressed as fold change of the average and displayed in a heatmap. All oligonucleotide primers are compiled in Supplementary Table S1.

Microscopy

IHC for the F4/80 macrophage marker was performed as previously described (23).

Statistical analysis

Survival for differentially treated mice was compared using the Kaplan–Meier method and the log-rank (Mantel–Cox) test. Additional statistical methods are stated in the figure legends. All P < 0.05 were considered statistically significant.

Results

Infiltration of tumor-specific CD8 T cells coincides with influx of high numbers of macrophages into the tumors

Established TC-1 mouse tumors, which are transformed by the E6 and E7 oncogenes of HPV16, respond to prophylactic and therapeutic vaccination with an SLP, comprising the immunodominant E7 peptide emulsified in the mineral oil–based adjuvant IFA. Ten days after the start of therapy, the tumor-specific CD8 T-cell response is sufficiently elevated to mediate a robust regression of tumors with sizes up to 600 mm³. However, the independently derived HPV16 tumor line C3 responds to prophylactic but not to therapeutic vaccination with the same SLP vaccine modality (5, 19). To better understand these differences, we analyzed tumor-infiltrating leukocytes 10 days after peptide vaccination, when TC-1 tumors just start to regress but C3 tumors continue to grow. It became apparent that peptide vaccination induced an abundant infiltration of E7-specific, IFNγ- and TNFα-producing CD8 T cells in TC-1 tumor (Fig. 1A–C) but not in C3 tumors (Fig. 1D–F). Interestingly, SLP vaccination also induced an extensive increase of the F4/80+/CD11b+ macrophage population in the TC-1 model (3.3-fold enhanced compared with untreated) but not in the C3 tumor model (Fig. 1G vs. H). Because CD8 T-cell depletion in vaccinated TC-1 tumor-bearing mice fully abrogated the SLP vaccine–induced macrophage increase, we concluded that CD8 T cells are essential for an enhanced myeloid tumor infiltration. This conclusion was confirmed by our observation that CD4 depletion had no effect on vaccine-induced changes (Fig. 1G) and that mice that were injected with an empty IFA depot had a comparable myeloid cell tumor infiltration as untreated tumors (Supplementary Fig. S1A).

Inflammatory macrophages are the dominant cells in peptide-treated TC-1 tumors

Characterization of the intratumoral myeloid population (CD45⁺CD3⁻CD11b⁺) by flow cytometry allowed the
Identification of distinct subsets, based on differential expression of the macrophage marker F4/80 and the activation marker Ly6C (Fig. 2A). To gain insight into the identity of these distinct myeloid subsets in the two models, we examined the expression levels of CD11c, MHC-II, and Ly6G (Fig. 2B and C). We could delineate four subsets: "inflammatory macrophages" (F4/80hiLy6Ghi) with intermediate levels of CD11c and MHC-II (population 1); "tissue-resident macrophages" (F4/80loLy6Ghi, population 2); DC-like macrophages (F4/80hiLy6Cint) with the highest expression of CD11c and MHC-II (population 3); and granulocytic myeloid macrophages (F4/80loLy6Cint, population 4). The myeloid profile of untreated TC-1 tumors strongly differed from that of TC-1 tumors from SLP-vaccinated mice, even though tumor sizes were comparable at the time of analysis (Supplementary Fig. S1B).

Peptide vaccination enhanced the presence of all myeloid subsets between 2-fold and 8-fold (Fig. 2D), but inflammatory macrophages increased the most, around 8-fold. Tissue-resident macrophages (population 2) was the most prominent subset in untreated tumors, whereas inflammatory macrophages (population 1), expressing high levels of Ly6G, dominated the SLP-vaccinated tumors (Fig. 2C). The observation that infiltration of the inflammatory macrophages was significantly correlated to CD8 T-cell infiltration confirmed our observation that CD8 T cells are essential for myeloid cell infiltration. In C3 tumors of SLP-treated mice, there were no differences in the frequencies of these subsets. Furthermore, in TC-1 tumors, but not in C3 tumors, peptide vaccination resulted in increased CD11c expression on all myeloid population, a more uniform expression of class II on population 2 and a decreased Ly6G expression on population 4 (Fig. 2B and D), indicating that only successful therapeutic vaccination altered the activation status of the different myeloid subsets. Together, these data demonstrated that a vaccine-induced tumor regression phase is precluded by a strong recruitment of CD11b+ F4/80+ Ly6C+ macrophages into tumors. Because these differences appeared only in tumors with a dense CD8 T-cell infiltration, we concluded that vaccine-induced CD8 T cells are essential for this myeloid modulation.

Infiltration of tumor-specific CD8 T cells enhances the levels of macrophage-attracting chemokines

Next, we tested how CD8 T cells would modulate myeloid cell infiltration. Because various chemokines have been linked to the attraction of inflammatory macrophages, we analyzed chemokine gene expression on whole-tumor material and detected increased CCL2 levels in tumors of SLP-vaccinated mice compared with that of untreated tumors (Fig. 3A). The levels of monocyte-attracting chemokines CCL5 and CCL12 as well as the T cell–attracting chemokines CXCL9, CXCL10, and CXCL11 clearly increased upon peptide vaccination (Fig. 3A). When TC-1 tumor cells were co-cultivated in vitro with TNFα and IFNγ, two cytokines produced by SLP-vaccination-induced intratumoral T cells (Fig. 1; ref. S), a striking increase in CCL2, CCL5, and CXCL10 gene expression was observed (Fig. 3B). CXCL9 and CXCL11 were undetectable in untreated and single-treated samples but clearly evident upon combined incubation with both IFNγ and TNFα (data not shown). Interestingly, similar chemokine levels were induced by IFNγ-treated and/or TNFα-treated C3 tumor cells (Fig. 3C), indicating that the capacity of C3 tumor cells to produce myeloid- and T cell–attracting chemokines did not differ from that of TC-1 tumor cells. Analysis of whole TC-1 tumors revealed that, although Arginase-1 and CXCL2 levels were similar between control and treated groups, tumors from vaccinated mice showed a tendency toward enhanced levels of the myeloid marker CD11b, confirming that vaccination enhanced myeloid infiltration. Moreover, the enhanced expression of CD74, the invariant chain chaperone of MHC class II, and FcRγ, the common gamma chain of Fc receptors for IgG, confirmed the activated phenotype of infiltrated myeloid subsets. Together, these data indicated that stimulated tumor cells express enhanced levels of monocyte- and T cell–attracting chemokines. Because the attraction of T cells appeared crucial for the observed myeloid changes (Figs. 1 and 2), this strongly suggests that the levels of T cell–produced cytokines within the tumor bed are crucial for myeloid attraction to and alterations within the tumor.

PLX3397 selectively removes tissue-resident macrophages and DC-like myeloid cells

Next, we dissected the role of intratumoral macrophages and their function in vaccine-induced tumor rejection responses as observed in the TC-1 tumor model. To this end, we used the tyrosine kinase inhibitor PLX3397. TC-1 tumor cells did not express the PLX3397-targeted receptors CSF-1R and c-Kit (data not shown), precluding direct effects of the compound on tumor cells. In concordance with previous studies, PLX3397 primarily deleted intratumoral macrophages (Supplementary Fig. S2), as the numbers of liver and spleen macrophages appeared unaffected (Supplementary Fig. S3; refs. 21, 22).

F4/80+ cells were scarcely present in tissue sections of TC-1 tumors after PLX3397 application as determined by IHC (Supplementary Fig. S2) and flow cytometry (Fig. 4A). In SLP-vaccinated mice, PLX3397 treatment also clearly reduced the total number of macrophages, although a small portion remained. Together, these data demonstrate a strong reduction of intratumoral macrophages by the small-molecule inhibitor PLX3397.

Importantly, treatment with PLX3397 did not change the total number, the antigen specificity, or cytokine production by systemic (Fig. 4B and C) or intratumoral CD8 T cells (Fig. 4D–F). Furthermore, no changes in the vaccine-induced specificity of CD8 T cells were detected in the lymph nodes and blood of non–tumor-bearing mice (Supplementary Fig. S4). We concluded that PLX3397 did not affect vaccine-mediated T-cell priming, effector functions, or homing, but strongly reduced the numbers of intratumoral macrophages.

Tumor regression depends on macrophages

Next, we examined the effect of PLX3397 on vaccine-induced tumor-rejection responses. Mice bearing TC-1 tumors were treated in the presence or absence of PLX3397. SLP vaccination on day 10 after tumor inoculation resulted in strong regressions of large established tumors (Fig. 5A). Depletion of CD8+ T cells completely abolished tumor control, indicating that CD8+ T cells are crucial for peptide-induced antitumor responses (Fig. 5A). Accordingly, control vaccination had no effect on tumor growth, supporting the fact that tumor-specific T cells are indispensable for tumor regressions (data not shown).

Strikingly, PLX3397 application during peptide vaccination abrogated the typical complete tumor regressions (Fig. 5A and B). After initial reduction in tumor sizes, progressive tumor growth was observed (Fig. 5A and B). Tumor sizes initially decreased in vaccine-treated animals, but these regressions were not sustained in the absence of macrophages. Application of the
Figure 2.
Vaccination with SLP massively enhances numbers of macrophage subsets. TC-1 tumors and C3 tumors were resected 10 days after vaccination and single-cell suspensions of infiltrating cells were analyzed by multicolor flow cytometry. A, Flow cytometry plots are shown for F4/80 and Ly6C staining of tumor-infiltrating myeloid cells in untreated (left) and peptide-treated (right) tumors. Four different subpopulations were distinguished. B, the expression of CD11c, MHC-II, and Ly6G on each subpopulation of untreated TC-1 tumors (filled histograms) and TC-1 tumors treated with SLP vaccine (solid lines). C, geometric means of CD11c (left), MHC II (middle), and Ly6G (right) on all four tumor-infiltrating subsets are shown. D, percentages of the four different myeloid cell subsets were determined for both tumor types. Data shown for TC-1 are representative of three independent experiments with 5 animals per group. (Continued on the following page.)
CSF-1R inhibitor alone did not lead to any change in tumor outgrowth. Depletion of intratumoral macrophages by PLX3397 resulted in survival curves that were comparable with those of T cell–depleted animals (Fig. 5C). Additionally, the more specific but weaker CSF-1R inhibitor PLX5622 (24) abrogated the peptide-induced tumor regression (Supplementary Fig. S5). Together, our data illustrate how SLP vaccination causes substantial changes in the myeloid cell composition of tumors and, moreover, indicate that the induction of this major inflammatory population of macrophages is required for successful and more sustained tumor-regression responses.

Discussion
Successful tumor-rejection responses evoked by long-peptide vaccines depend on tumor-specific CD8 T cells and, as we show here, also on intratumoral macrophages. The typical steep shrinkage of tumors that starts 10 days after SLP vaccination was abrogated in the presence of PLX3397, an inhibitor of the myeloid receptor CSF-1R and c-Kit (21, 22), and in the presence of PLX5622, a weaker but selective CSF-1R inhibitor (24). Upon inhibition of intratumoral macrophages an initial stabilization of tumor sizes was followed by rapid regrowth, instead of shrinkage. Because only those tumors with a clear infiltration of IFNγ- and TNFα-producing, tumor-specific CD8 T cells displayed altered myeloid subsets (Figs. 1 and 2), we conclude that cytotoxic CD8 T cells have the capacity to deploy a tumor-rejection response by local attraction and skewing of macrophages in the TME. In addition to the well-known CD4 T cell function by linear regression; test;

(CZ) Published OnlineFirst April 17, 2015; DOI: 10.1158/2326-6066.CIR-15-0052

Because peptide vaccination can induce a dense infiltration of TNFα- and IFNγ-producing CD8 T cells, it is likely that these cytokines are involved in the modulation of intratumoral myeloid cells in our model. Previously, we and others have shown that IFNγ can overcome cancer-induced M2-type differentiation (16, 28). Here, we show that coinubation of two HPV16-transformed tumor cell lines with TNFα and IFNγ enhances the expression of various chemokines that are known to mediate the recruitment of (inflammatory) macrophages to the tumor. Furthermore, C3 tumors and CD8 T cell–depleted TC-1 tumors showed no altered myeloid cell infiltration. Only tumors infiltrated with cytokine-producing T cells and a large number of inflammatory macrophages, and a similar chemokine profile as found in tumor cells incubated with IFNγ and TNFα. The link

(Continued) Data shown for C3 are from one experiment with 4 to 5 mice per group. All data are expressed as mean with standard error of the mean (SEM; Student t test; *, P < 0.05; **, P < 0.01). E, correlation between the percentages of CD8 T cells (horizontal axis) and the four subsets (vertical axis) within resected tumors of vaccinated mice. Each dot represents data from an individual mouse; data shown are pooled from three independent experiments. The data were analyzed by linear regression; R2 and P values are indicated in the figure.

www.aacrjournals.org Cancer Immunol Res; 3(9) September 2015
between CCL2 and monocyte attraction has been reported (29). In fact, in 1983, CCL2 was already described as a tumor-derived chemotactic factor (30) and has since been linked to the abundance of TAMs in many tumors (31). Furthermore, Popivanova and colleagues (32) showed that TNFα-induced CCL2 enhanced infiltration of macrophages in colon tumors. CCL5 was strongly induced by the combination of IFNγ and TNFα (Fig. 3; refs. 33, 34) and has been implicated in the attraction and survival of macrophages in adipose tissue (35) and various tumors (36, 37). Together, these data show that cytokines can directly or indirectly skew and attract myeloid cells. The ability of cytokine-producing T cells to skew myeloid subsets is emphasized by the observation that the absence of CCL2 in skin wounds also decreases macrophage infiltration (38). At the same time, modified macrophages within the tumor might boost an antitumor type 1 inflammatory response (39) and previous studies showed that CSF-1R-triggering enhanced the tumoricidal capacity of macrophages (40). Importantly, these studies together reveal the large plasticity of the intratumoral myeloid population and indicate that conventional and immune-based treatments can polarize the tumor-promoting function of macrophages into tumor-rejection responses.

Targeting of macrophages with CSF-1R inhibitors paradoxically enhanced overall survival in various mouse tumor models, especially when combined with other forms of immunotherapy, chemotherapy, or with radiotherapy (21, 22, 38, 41–43). We hypothesize that the critical factor to explain this discrepancy is the capacity of the treatment to functionally polarize macrophages toward a tumor-rejection activity. Our SLP vaccination clearly induced high levels of IFNγ and TNFα in the local TME and thereby inducing the polarization of the resident tumor-promoting macrophages into M1-type of cells. If the antitumor treatment is not capable of such strong polarization, the treatment efficacy can be enhanced by removing macrophages via CSF-1R inhibition. Moreover, most mouse tumor models evaluate growth delay or control, but not actual regressions, which might depend on other macrophage subsets. Combination therapies with CSF-1R inhibitors, such as adoptive T-cell...
Intratumoral macrophages are required for SLP vaccine-induced tumor regression. A, TC-1 tumor outgrowth of individual mice. B, mean tumor sizes of living animals are depicted per group together with standard error of the mean. Shown are three groups: untreated (n = 14), SLP vaccinated (peptide; n = 26), and SLP vaccination in the presence of PLX3397 (peptide + PLX; n = 26). Statistically significant differences are observed at day 21 and onward (Student t test; *, P < 0.01; **, P < 0.001). C, the Kaplan–Meier survival curves for different treatment regimens; shown are pooled data from three experiments (log-rank analysis ***, P < 0.001).

therapy, usually include systemic inflammatory factors, such as total body irradiation or strong adjuvants such as the TLR-7 agonist imiquimod (22, 42, 44). These inflammatory factors might be capable of skewing the phenotypes of macrophages, but they might not have such a strong impact on the local TME as infiltrating CD8 T cells. Therefore, a positive versus negative contribution of TAMs to tumor eradication might depend on the size and quality of the natural or vaccine-induced T-cell response and the unique abilities of the adjuvants provided along with the therapies.

We therefore conclude that harnessing macrophage targeting for cancer therapy needs careful reappraisal. Deciphering the exact molecular cues responsible for macrophage polarization during treatment seems critical for effective therapy. Recently, we have demonstrated a positive correlation of a dense infiltration of M1-type macrophages with patient survival in a cohort of cervical cancer patients (45), supporting the notion that macrophage skewing toward antitumor activity, rather than macrophage depletion, might be the optimal strategy. Our study illustrates that immunogenic cancer vaccines can be instrumental to induce such a repolarization of intratumoral macrophages.

Disclosure of Potential Conflicts of Interest

C.J.M. Melief reports receiving a commercial research grant from ISA Pharmaceuticals. S.H. van der Burg is an Advisor Immunomonitoring at Dutch Cancer Institute and is a consultant/advisory board member for ISA Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: T.C. van der Sluis, C.J.M. Melief, R. Arens, S.H. van der Burg, T. van Hall
Development of methodology: T.C. van der Sluis
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T.C. van der Sluis, S. van Duikeren, B.L. West
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T.C. van der Sluis, S. van Duikeren, C.J.M. Melief, R. Arens, T. van Hall
Writing, review, and/or revision of the manuscript: T.C. van der Sluis, B.L. West, C.J.M. Melief, R. Arens, S.H. van der Burg, T. van Hall
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Sluijter, S. van Duikeren, T. van Hall
Study supervision: R. Arens, S.H. van der Burg, T. van Hall

Acknowledgments

The authors thank W. Benckhuijsen and J.W. Drijfhout for providing peptides, K. Franken for providing tetramers, and K.A. Manjri for his help in figure preparation of the heatmap.

Grant Support

This work was supported by a grant from the Dutch Cancer Society (2009-4400, to C.J.M. Melief and S.H. van der Burg).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 24, 2015; revised April 3, 2015; accepted April 6, 2015; published OnlineFirst April 17, 2015.
References
7. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
9. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
10. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor asso-
11. van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber...
12. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance,
13. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG,
14. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG,
15. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG,
21. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
22. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
23. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
24. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
25. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
26. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
27. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
28. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
29. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
30. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerper-...
32. Popivanova BK, Kostadinova FI, Furusi K, Shamel MT, Kerper-A,...


Correction: Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

In this article (Cancer Immunol Res 2015;3:1042–51), which appeared in the September 2015 issue of Cancer Immunology Research (1), the shared last authorship contribution of Sjoerd van der Burg and Thorbald van Hall was not indicated. The editors regret this omission.

The online PDF and HTML versions of the article have been corrected and supersede the printed version.

Reference

Published OnlineFirst October 6, 2015.
doi: 10.1158/2326-6066.CIR-15-0246
©2015 American Association for Cancer Research.
Cancer Immunology Research

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

Tetje C. van der Sluis, Marjolein Sluijter, Suzanne van Duikeren, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-15-0052

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2015/04/16/2326-6066.CIR-15-0052.DC1

Cited articles
This article cites 45 articles, 21 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/3/9/1042.full#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/3/9/1042.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://cancerimmunolres.aacrjournals.org/content/3/9/1042
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.